In a phase I study, a vaccine targeting intracellular domains of HER2 (amino acids 676 to 1255 of the full-length HER-2/neu) demonstrated the immunogenic profile in 29 HER2+ breast and ovarian cancer patients. The gene discussed is ERBB2; the disease is ovarian carcinoma.